Search Within

Diana E Lake

Formats
  1. Meeting Abstract (48)
  2. Journal Article (39)
  3. Book Whole (1)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (89)
  2. Department of Medicine (89)
  3. Solid Tumor Oncology Division (89)
  4. Survivorship Research (89)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (55)
  6. Epidemiology and Biostatistics (48)

More Groups

People
  1. Clifford Hudis (65)
  2. Larry Norton (45)
  3. Gabriella D'Andrea-Carlino (39)
  4. Chau Dang (37)
  5. Monica Fornier (36)
  6. Maura Dickler (33)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (4)
  5. 2021 (1)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Cancer Research (16)
  3. Breast Cancer Research and Treatment (13)
  4. Clinical Breast Cancer (7)
  5. Clinical Cancer Research (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (20)
  3. Springer (14)
  4. Elsevier Inc. (9)
  5. Oxford University Press (3)
  6. American Medical Association (2)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients
    Meeting Abstract

    Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Journal Article

    Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Wang, R.; Singh, J.; Sterlin, V.; Goldstein, M.; Lake, D.; Wong, S.; Baselga, J.; Norton, L.; Dang, C.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy for node negative, high Recurrence Score(TM) breast cancer: In defense of de-escalation
    Editorial

    Lake, D.; Seidman, A. D.
    npj Breast Cancer (2019)

    Fulltext@MSK | Save
  • Co-targeting ER and FGFR in patients with ER+/HER2- FGFR amplified (amp) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Syed, U.; Wong, S.; D'Andrea, G.; Lake, D.; Goldfarb, S.; Gajria, D.; Ligresti, L.; Rogado, A.; Reis-Filho, J.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • First-in-human human epidermal growth factor receptor 2-targeted imaging using (89)Zr-Pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer
    Journal Article

    Ulaner, G. A.; Lyashchenko, S. K.; Riedl, C.; Ruan, S.; Zanzonico, P. B.; Lake, D.; Jhaveri, K.; Zeglis, B.; Lewis, J. S.; O'Donoghue, J. A.
    Journal of Nuclear Medicine (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials
    Journal Article

    Basch, E.; Dueck, A. C.; Rogak, L. J.; Minasian, L. M.; Kelly, W. K.; O'Mara, A. M.; Denicoff, A. M.; Seisler, D.; Atherton, P. J.; Paskett, E.; more...
    JAMA Oncology (2017)

    Fulltext@MSK | Save